



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: 乌地那非
产品别名: **Udenafil ; DA8159**

生物活性:																					
Description	Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction. Target: PDE5 Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction [1]. After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) ($P < 0.0001$). udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) ($P < 0.0001$) [2].																				
	In Vitro: DMSO : ≥ 33 mg/mL (63.87 mM) <small>* "≥" means soluble, but saturation unknown.</small> <table><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent Mass Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>1 mM</th><td>1.9355 mL</td><td>9.6775 mL</td><td>19.3551 mL</td></tr><tr><th rowspan="2"></th><th>5 mM</th><td>0.3871 mL</td><td>1.9355 mL</td><td>3.8710 mL</td></tr><tr><th>10 mM</th><td>0.1936 mL</td><td>0.9678 mL</td><td>1.9355 mL</td></tr></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> In Vivo: <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (4.84 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀, 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂: 10% DMSO →90% corn oil Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (4.84 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p>				Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	1 mM	1.9355 mL	9.6775 mL	19.3551 mL		5 mM	0.3871 mL	1.9355 mL	3.8710 mL	10 mM	0.1936 mL	0.9678 mL
Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg																	
	1 mM	1.9355 mL	9.6775 mL	19.3551 mL																	
	5 mM	0.3871 mL	1.9355 mL	3.8710 mL																	
	10 mM	0.1936 mL	0.9678 mL	1.9355 mL																	



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

	以 1 mL 工作液为例, 取 100 μ L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μ L 玉米油中, 混合均匀。
References	<p>[1]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7.</p> <p>[2]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.</p>



源叶生物